Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 shareholder update highlighting key clinical milestones and a proposed pipeline expansion through the acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor targeting EGFR-mutated lung cancer and other cancers. The company intends to acquire CL-741 from Celyn Therapeutics, complementing its existing portfolio of oncology candidates.
CL-741 is designed to address EGFR-mutated lung cancer and other malignancies, and Kairos expects to initiate a Phase 1 study of the drug. This addition would bolster a pipeline that already includes ENV-105, KROS-201, KROS-102, and ENV-205. The company also plans to advance ongoing clinical trials of ENV-105 in castrate-resistant prostate cancer and non-small cell lung cancer, present data at scientific meetings, and pursue pharmaceutical collaborations.
In its update, Kairos noted it has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs. This funding is expected to help advance the company's lead candidate, ENV-105, an antibody targeting CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The expansion of Kairos Pharma's pipeline with CL-741 represents a strategic move to target lung cancer, one of the most prevalent and deadly cancers worldwide. The oral c-MET kinase inhibitor could offer a new treatment option for patients with EGFR-mutated lung cancer who develop resistance to existing therapies. If successful, CL-741 may fill an important gap in the oncology treatment landscape.
Kairos Pharma is based in Los Angeles, California, and focuses on oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's progress in clinical trials and its ability to secure non-dilutive funding underscore its commitment to advancing cancer treatments.
For more information, visit the company's newsroom at https://ibn.fm/KAPA and the full press release at https://ibn.fm/WuBOf.
